Findings offer promising implications for neuroscience clinical trials and future treatments, company says.
Clario, a healthcare research technology company, revealed in a company press release that researchers at Oxford University have successfully developed a new understanding of motor symptom progression in Parkinson's Disease through the use of its Precision Motion Opal technology. Reportedly, a study that leveraged the company’s wearable sensors and machine learning enabled researchers with the ability to track the motor symptom progression in individuals with Parkinson's Disease (PD) better than the conventionally used clinical rating scales. Additionally, results found that the device discovered disease progression in a significantly shorter timeframe than the traditional method.
"We are honored to support Professor Antoniades with her pivotal research and are very excited about the positive implications of these results on the Parkinsonism field," said Kristen Sowalsky, PhD, DC, VP of Medical & Scientific Affairs, Clario. "This breakthrough demonstrates the essential benefit of using wearable technology and machine learning algorithms to track Parkinson's Disease progression more accurately and assess the efficacy of early therapeutic intervention. The potential impact of these findings for neuroscience clinical trials is outstanding."
Reference: Clario's Precision Motion Opal® technology powers University of Oxford breakthrough in Parkinson's Disease. PR Newswire. October 27, 2023. Accessed October 31, 2023. https://www.prnewswire.com/news-releases/clarios-precision-motion-opal-technology-powers-university-of-oxford-breakthrough-in-parkinsons-disease-301969111.html
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.